Stock Traders Buy High Volume of Genmab A/S Call Options (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the recipient of unusually large options trading on Wednesday. Investors bought 4,002 call options on the stock. This is an increase of approximately 169% compared to the average volume of 1,487 call options.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on GMAB shares. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and increased their price target for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Weiss Ratings raised Genmab A/S from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Guggenheim raised their target price on Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Truist Financial began coverage on Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price on the stock. Finally, New Street Research set a $43.00 price target on shares of Genmab A/S in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.50.

Genmab A/S Trading Up 1.0%

Shares of NASDAQ:GMAB opened at $34.10 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The stock has a market capitalization of $21.26 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 2.00 and a beta of 0.83. Genmab A/S has a 1-year low of $23.62 and a 1-year high of $35.43. The company has a 50 day moving average price of $29.53 and a 200 day moving average price of $27.99.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. On average, research analysts anticipate that Genmab A/S will post 1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after purchasing an additional 1,174 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Genmab A/S by 4.2% in the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after purchasing an additional 2,496 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after purchasing an additional 81,434 shares in the last quarter. Quantinno Capital Management LP boosted its position in shares of Genmab A/S by 64.9% in the second quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after buying an additional 62,226 shares during the period. Finally, Raymond James Financial Inc. boosted its position in shares of Genmab A/S by 48.1% in the second quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after buying an additional 10,113 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.